AU2001265187A1 - Chimeric viral vectors for gene therapy - Google Patents

Chimeric viral vectors for gene therapy

Info

Publication number
AU2001265187A1
AU2001265187A1 AU2001265187A AU6518701A AU2001265187A1 AU 2001265187 A1 AU2001265187 A1 AU 2001265187A1 AU 2001265187 A AU2001265187 A AU 2001265187A AU 6518701 A AU6518701 A AU 6518701A AU 2001265187 A1 AU2001265187 A1 AU 2001265187A1
Authority
AU
Australia
Prior art keywords
gene therapy
viral vectors
chimeric viral
chimeric
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265187A
Inventor
Estuardo Aguilar-Cordova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2001265187A1 publication Critical patent/AU2001265187A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
AU2001265187A 2000-05-30 2001-05-30 Chimeric viral vectors for gene therapy Abandoned AU2001265187A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20784500P 2000-05-30 2000-05-30
US60207845 2000-05-30
PCT/US2001/017453 WO2001091802A1 (en) 2000-05-30 2001-05-30 Chimeric viral vectors for gene therapy

Publications (1)

Publication Number Publication Date
AU2001265187A1 true AU2001265187A1 (en) 2001-12-11

Family

ID=22772212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265187A Abandoned AU2001265187A1 (en) 2000-05-30 2001-05-30 Chimeric viral vectors for gene therapy

Country Status (3)

Country Link
US (1) US20060057553A1 (en)
AU (1) AU2001265187A1 (en)
WO (1) WO2001091802A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0973928T3 (en) 1997-03-11 2010-08-09 Univ Minnesota DNA-based transposon system for introducing nucleic acid into DNA in a cell
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
GB2355459B (en) 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
RU2539099C2 (en) * 2009-04-13 2015-01-10 Апцет Гмбх Унд Ко.Кг Engineered mesenchymal stem cells and method for using them for treating tumours
BR112013027500A2 (en) 2011-04-29 2017-01-10 Selecta Biosciences Inc controlled release of synthetic nanotransport immunosuppressants
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
CN105283175A (en) 2013-05-03 2016-01-27 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects
DK3116900T3 (en) * 2014-03-09 2020-09-28 Univ Pennsylvania COMPOSITIONS THAT CAN BE USED TO TREAT ORNITHIN TRANSCARBAMYLASE (OTC) DEFECT
GB2526867A (en) 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
CN107073050A (en) 2014-09-07 2017-08-18 西莱克塔生物科技公司 The method and composition of antiviral transfer vector immune response is treated for reducer
WO2016118433A1 (en) * 2015-01-20 2016-07-28 Shayakhmetov Dmitry M Detargeted adenovirus variants and related methods
BR112018010635A2 (en) * 2015-11-24 2018-11-27 Glaxosmithkline Ip Dev Ltd stable cell lines for retroviral production
RU2749717C2 (en) 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Method for temporary transfection for producing retrovirus
WO2017123918A1 (en) * 2016-01-15 2017-07-20 American Gene Technologies International Inc. Methods and compositons for the activation of gamma-delta t-cells
US10767183B2 (en) 2016-03-09 2020-09-08 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
WO2018009246A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. Viral vectors for treating parkinson's disease
WO2018029534A1 (en) 2016-08-12 2018-02-15 Oxitec Ltd. A self-limiting, sex-specific gene and methods of using
BR112019013862A2 (en) 2017-01-07 2020-04-14 Selecta Biosciences Inc standard dosage of immunosuppressants coupled to synthetic nanocarriers
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018187231A2 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
JP2022506515A (en) 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Vector system for expressing regulatory RNA
CN114126666A (en) 2019-04-28 2022-03-01 西莱克塔生物科技公司 Methods for treating subjects with pre-existing immunity to viral transfer vectors
CN114901297A (en) * 2019-10-16 2022-08-12 卡利威尔免疫治疗公司 Producer virus for in situ generation of retroviruses
CN115044614B (en) * 2021-03-09 2023-10-20 上海目镜生物医药科技有限公司 Modified vector of AAV-8 serotype for gene targeting and expression, construction method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001650A (en) * 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US20020048805A1 (en) * 1998-01-16 2002-04-25 Julie C. Johnston Feline immunodeficiency virus gene therapy vectors

Also Published As

Publication number Publication date
WO2001091802A1 (en) 2001-12-06
US20060057553A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AU2001265187A1 (en) Chimeric viral vectors for gene therapy
AU2001291656A1 (en) Gene silencing vector
AU1152402A (en) Highly expressible genes
AU2001234981A1 (en) Adenoviral capsid containing chimeric protein ix
AU3358999A (en) Chimeric adenoviral vectors for targeted gene delivery
AU2003238456A1 (en) Viral vector
AU769385C (en) Virus envelope vector for gene transfer
AU2002219841A1 (en) Vectors for conditional gene inactivation
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
AU2001238079A1 (en) Antibody gene therapy with adeno-associated viral vectors
AU2001280576A1 (en) Tissue-specific self-inactivating gene therapy vector
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU2001246703A1 (en) Dna immunization vectors
AU2001242625A1 (en) Gene sequence
AU2001264247A1 (en) GASC1 gene
AU2002337892A1 (en) Vectors for expressing multiple transgenes
AU2001287976A1 (en) Chimeric vectors and their use for heterologous genes transfer
AU2001240103A1 (en) Reproduction-specific genes
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2001288839A1 (en) Self-rearranging dna vectors
AUPQ749100A0 (en) New epilespy gene
GB0008966D0 (en) Vectors for gene therapy
AU6983000A (en) Chimeric proteins
AU7567101A (en) Gene expression system
AU2002316788A1 (en) Retroviral vectors for gene therapy